Introduction {#sec1-1}
============

Botswana remains a country heavily affected by tuberculosis (TB), with an estimated 2015 incidence of 356 per 100,000 in the population.^[@ref1]^ TB has seen a resurgence in part due to the burden of the human immunodeficiency virus (HIV); roughly 60% of all individuals with TB in Botswana have underlying HIV.^[@ref1]^ The diagnosis of HIV-related TB is particularly challenging as patients often present with acid-fast bacilli (AFB) smear negative disease.^[@ref2]^ Prior studies have demonstrated that sputum smear-negative TB accounts for 22% of pulmonary TB in Botswana, and is consistent with the high prevalence of HIV in the area.^[@ref3],[@ref4]^ Use of nucleic-acid amplification tests (NAAT) has enhanced the ability to diagnose HIV-TB, however challenges remain in widespread implementation.^[@ref5]^

Marked delays in TB diagnosis risk exposure of close contacts, transmission of TB and worsened outcomes.^[@ref6]^ TB may present as an acute respiratory illness, mimicking or occurring concomitantly with communityacquired pneumonia (CAP), which could contribute to diagnostic delays, increasing the likelihood of TB transmission.^[@ref7]^ Indeed, TB represents the leading respiratory illness among hospitalized HIV-infected individuals in Botswana.^[@ref8]^ Among those with a microbiologic diagnosis of CAP, one South African study found *Mycobacterium tuberculosis* (MTB) in 39.6% of sputa. In this South African cohort, MTB was the most common cause of CAP in both HIV-positive and HIVnegative patients. Among those with HIV, 26% of those who died had microbiologically confirmed TB.^[@ref9]^

TB is not routinely considered a leading cause of CAP, so specific screening may not be performed. Identifying TB among patients presenting with respiratory illness affords the chance to appropriately target therapy and improve outcomes. In this study, we sought to identify opportunities to diagnose TB earlier. Our primary objective was to determine the frequency of TB among patients presenting with CAP to a large referral hospital in Gaborone, Botswana. The secondary objective was to define factors, including HIV status, associated with a diagnosis of TB in this setting.

Materials and Methods {#sec1-2}
=====================

Study population {#sec2-1}
----------------

We extracted data captured in the Emergency Department electronic database and hospital charts for patients presenting with CAP to Princess Marina Hospital (PMH), a 567-bed public tertiary hospital in Gaborone, Botswana. We included persons age 18 years or older, presenting from April 2010 through September 2011 with the diagnosis of CAP. We included all patients with diagnoses of *pneumonia*, *communityacquired pneumonia*, and *Pneumocystis jirovecii (PCP) pneumonia*, given that the last is a presumptive clinical diagnosis with a lack of reliable microbiologic certainty in Botswana. Confirmed diagnoses, with new chest radiograph findings, and presumed diagnoses, without chest radiography performed, were included, given the intermittent availability of chest radiography. Additional diagnoses of *chest infection* and *lower respiratory tract infection* were included if they satisfied the following criteria: i) at least one new chest symptom within the preceding two weeks, including new or worsened cough, shortness of breath, pleuritic chest pain, and ii) fever (T\>38.0°C) or hypothermia (T\<36.0°C). Repeated visits within 10 days were excluded.

The patients identified with CAP were matched to the National Botswana Tuberculosis Registry (NBTR) to identify individuals who were subsequently diagnosed with TB. Matches were made based upon identification (known as Omang) numbers or passport numbers when available, and manually by name, when identification numbers were not provided. Patients with a date of TB diagnosis in the NBTR prior to CAP diagnosis in the Emergency Department were excluded. Those with a missing data entry for TB treatment outcome were considered lost to follow up.

In patients who were diagnosed with CAP we assessed the following characteristics: demographics including age, sex, HIV status; chest radiograph findings (when available); hospital disposition; presenting symptoms including cough, fever, night sweats, shortness of breath, weight loss, fatigue, vomiting, hemoptysis; history of TB; time to TB diagnosis; sputum smear result. Laboratory data such as sputum culture were not routinely available for all subjects matched to the NBTR and sputum for bacterial cultures are not routinely collected. The primary outcome was registration of TB diagnosis within 90 days of presentation with CAP, as determined from the NBTR.

Statistical analysis {#sec2-2}
--------------------

Demographic frequencies of those with CAP were calculated using STATA version 12.^[@ref10]^ Chi-squared analyses were used to compare demographics across patients grouped by CAP with TB and CAP without TB. Logistic regression was used to compare sputum smear results and known HIV statuses using odds ratios (ORs) with confidence intervals (CIs). All statistical tests assessed significance at the 5% level.

This study was approved by the Institutional Review Boards of the University of Pennsylvania, the Botswana Ministry of Health, and Princess Marina Hospital.

Results {#sec1-3}
=======

Study population {#sec2-3}
----------------

Of 37,053 adults presenting to the PMH Emergency Department from April 2010 through December 2011, 1516, or 4.1%, were diagnosed with CAP ([Figure 1](#fig001){ref-type="fig"}). Of all individuals presenting with CAP, 14 individuals either died in the Emergency Department or were deceased upon arrival. Two hundred and eleven were excluded from matching with the NBTR due to their presentation fewer than 90 days from the end of the study period, and 27 were excluded due to their presence in the NBTR prior to their CAP presentation. Of the remaining 1278 adults presenting with CAP, 68, or 5.2%, matched to the NTBR.

Of the 68 CAP-TB matched patients, the median age was 35 (range 18-81) ([Table 1](#table001){ref-type="table"}). Thirty-one (46%) were female, and 36 (53%) were male; one patient had missing data. Fifty (74%) were HIV positive, seven (10%) were HIV negative, and 11 (16%) had unknown HIV status. In the Emergency Department, 14 individuals with HIV reported being on antiretroviral therapy (ART); NBTR records show 17 were taking ART while 9 were not. Of 61 patients who had chest radiography performed, 45 (74%) had positive chest x-ray findings, which included consolidations, opacities, effusions, and infiltrates, while 67% of individuals with CAP without TB had a positive chest x-ray. The disposition of the TB-CAP group was 34 admitted and 34 discharged.

Among the CAP-TB group matched to the NBTR, cough (77%) was the most common symptom. The frequency of symptoms was similar across both the matched and unmatched groups, except the matched group had a significantly higher frequency of night sweats (P-value 0.01). The matched group also had higher frequencies of hemoptysis (Pvalue 0.056) and weight loss (P-value 0.252) although these did not reach statistical significance ([Table 1](#table001){ref-type="table"}). Nineteen (28%) patients with a subsequent TB diagnosis, and 265 (22%) of those without, knew their prior history of TB disease.

TB diagnosis {#sec2-4}
------------

Among the matched CAP-TB group, 27 (40%) were sputum smear positive, 17 (25%) were sputum smear negative, 24 (35%) had unknown or missing sputum smear results. The median time from ED visit to diagnosis was 9.5 days. Four (6%) patients were diagnosed with TB the same day as presenting with CAP by AFB smear; 43 (63%) were diagnosed within 15 days of CAP presentation, and 60 (88%) within 90 days ([Figure 2](#fig002){ref-type="fig"}). The difference in time-to-diagnosis between the 27 smear positive patients and the 41 smear negative or unknown patients was 1 day (median 10 days for smear positive, 9 days for smear negative/unknown). When comparing above and below the median age, those 37 years and older were less likely to be diagnosed with TB within the study period \[OR 0.504 (95% CI 0.301, 0.844)\]. Of the 68 individuals who matched in the CAP-TB group, all were started on TB treatment per the NBTR records. Of the 16 whose treatment outcome was known from the NBTR records, 14 completed treatment, one defaulted on treatment, and one patient died. The remaining 52 patients who started on treatment per the National TB Registry were lost to follow up.

HIV status {#sec2-5}
----------

Eighty-four percent of those in the CAPTB group had a known HIV status. Both those with subsequent TB diagnoses and those without had an HIV positive rate of 87%. HIV negative individuals had an 83% smear positive rate, compared to approximately 50% smear positive rate among those with HIV. More people with HIV had sputum samples performed (29 samples) compared to HIV negative individuals (6 samples). Those with known HIV status were more likely to be diagnosed with TB within 90 days compared to those with unknown status \[OR 3.36 (95% CI 1.51, 7.48)\].

Discussion {#sec1-4}
==========

Derived from one of the largest samples of patients with CAP in sub-Saharan Africa, this study highlights the challenges in screening for TB in acute care settings and demonstrates opportunities for missed diagnosis in prevalent areas. Five percent of patients presenting with CAP were later registered in the National TB registry, representing a cohort of individuals who experienced a delay in diagnosis, risking transmission of TB to their families, in healthcare facilities and within the community. Not surprisingly, the majority of patients in our cohort also had underlying HIV and were more likely to present with smear-negative disease. The presence of HIV can further limit the diagnostic certainty of TB screening, as seen among these patients with a high HIV prevalence (87%) in a country with an HIV prevalence of 22%.^[@ref11]^ Our study demonstrates the lack of distinguishing clinical features between patients presenting with CAP and those with an underlying diagnosis of TB. There were no significant differences between the CAP-TB group and the CAP group regarding vital signs, respiratory symptoms, weight loss or night sweats. This supports the low specificity and known limitations in diagnostic value of a clinical symptom assessment, such as the WHO symptom screen, in HIV endemic areas.^[@ref12],[@ref13]^ In HIV care settings, the proportion of subclinical TB (sputum-culture positive with negative symptom screen) can approach 15% of new diagnoses. ^[@ref13]^ In an acute care setting, such as the Emergency Department, when alternative diagnoses are assigned based upon overlapping syndromes or negative symptom screens, subclinical TB may go undiagnosed in favor of another clinical diagnosis and timely initiation of therapy. As seen in a South African study of the microbiological diagnoses of CAP, *M. tuberculosis* was the most common pathogen isolated; however a microbiological diagnosis is infrequently available in clinical settings.^[@ref9]^ The line between CAP and TB can become blurred, especially in the context of HIV infection.

The Botswana antimicrobial guidelines recognize TB as a common cause of CAP and encourage sputum collection for AFB smear from those presenting with cough of greater than one week and all HIV positive individuals with concern for CAP.^[@ref14]^A third of patients presenting with CAP had unknown or missing sputum smear results, highlighting the challenges faced by patients and their providers in resource-constrained settings. Limitations in collecting sputum and long laboratory delays in releasing sputum smear results have been cited by Batswana physicians as obstacles to full implementation of the national TB guidelines.^[@ref3]^ This leads to a reliance on alternative diagnoses, tests, or empiric therapy in settings with a high proportion of smear-unknown or smear-negative TB, such as in HIV prevalent areas.^[@ref3]^ Negative sputum smear results can lead to delays in diagnosis or omission from further work up.^[@ref3],[@ref4]^ The WHO's 2010 endorsement of the Xpert MTB/RIF assay for TB investigation was a step towards an enhanced screening algorithm. Xpert MTB/RIF was successfully implemented in Botswana in 2011; however with an unsuccessful test incidence of up to 15%, continued efforts in training and improved sampling are needed.^[@ref16]^ Early studies found that in populations with high smear-negative rates of TB, such as HIVprevalent populations, screening with Xpert increased the case detection rate by 45% compared to smear microscopy.^[@ref5],[@ref15]^ Since the roll out of Xpert, studies in Botswana have shown that greater than half of positive sputum cultures among people living with HIV with a positive WHO symptom screen show non-tuberculous mycobacteria (NTM), demonstrating a significant limitation with reliance upon smear microscopy for diagnosis of TB, such as in our study.^[@ref17]^ Furthermore, our findings that TB was diagnosed no sooner with positive sputum smear raises concern for potential problems along the TB care cascade, such as laboratory delays, paucity of sputum sample collection, or clinician anchoring bias to CAP diagnosis.

HIV prevalence was high (87%) in CAP patients with subsequent TB and those without. More patients with HIV had sputum samples collected compared to those without HIV (29 samples *vs* 6 samples), which is likely related to an appropriately heightened clinical suspicion for TB among people living with HIV.^[@ref4],[@ref12],[@ref13],[@ref18]^ However, we saw a trend of positive smear results occurring more commonly in HIV negative individuals (83% smear positive rate) compared to HIV positive individuals (48% smear positive rate), supporting the often paucibacillary nature of HIV-associated TB.^[@ref19]^ Importantly, there was no difference in time to diagnosis for individuals with negative AFB smears compared to those with positive AFB smears, highlighting the delays in laboratory testing, processing of smear positive samples, and diagnosis among co-infected persons. While the effort to test for TB in HIV may be well intended, the diagnostic value of sputum smear is limited in HIV disease, and may contribute to the rate of false negative TB testing in HIV.^[@ref4],[@ref9],[@ref16]^

Our study was limited by the single site and retrospective study design. Charts often had incomplete or missing data, as seen with 35% of patients with missing or unknown sputum smear results. The study selected for those well enough to present to care for subsequent TB diagnosis after their Emergency Department visit. Those with chronic symptoms, which are more likely in TB disease, may not present to the Emergency Department, thus our sample may be an underestimation of TB disease presenting as CAP.^[@ref12]^ Furthermore we did not examine Emergency Department records for patients without CAP symptoms who nevertheless underwent evaluation for TB disease. Per the Botswana National TB Program 2011 guidelines, TB screening should include those with a history or new diagnosis of HIV.^[@ref20]^ Patients presenting to the Emergency Department with syndromes consistent with advanced HIV without CAP criteria were not included in our study. We suspect that our study underestimated the true proportion of missed TB diagnoses at this Emergency Department.

Conclusions {#sec1-5}
===========

The confirmation of TB following presentations with CAP highlights opportunities for missed TB diagnoses in acute care settings in high TB burden communities. Undiagnosed TB impacts the morbidity and mortality of individuals and the health of the community through unchecked transmission. Harnessing additional points of health care access to evaluate for TB, in the context of concurrent clinical syndromes, can positively affect the TB care cascade and the health of the community.
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###### 

Demographics of community-acquired pneumonia (CAP) presentations.

                                                                      CAP-TB (n=68), n (%)   CAP without TB (n=1210), n (%)   All (n=1278), n (%)
  ------------------------------------------------------------------- ---------------------- -------------------------------- ---------------------
  Median Age                                                          35                     38                               37
  HIV Status                                                                                                                  
  Positive                                                            50 (73.5)              780 (59.8)                       760 (59.5)
  Negative                                                            7 (10.3)               113 (8.7)                        109 (8.5)
  Unknown                                                             11 (16.2)              412 (31.6)                       409 (32.0)
  CXR ordered                                                         61 (89.7)              1016 (84.0)                      1077 (84.3)
  Positive Chest Radiograph Finding[\*](#tfn1){ref-type="table-fn"}   45/61 (73.8)           680/1016 (66.9)                  725/1077 (67.3)
  Disposition°                                                                                                                
  Admitted                                                            34 (50.0)              661/1186 (55.7)                  695/1254 (55.4)
  Discharged                                                          34 (50.0)              511/1186 (43.1)                  545/1254 (43.5)
  Cough                                                               52 (76.5)              875 (72.3)                       927 (72.5)
  Shortness of breath                                                 33 (48.5)              675 (55.8)                       708 (55.4)
  Night sweats                                                        20 (29.4)              208 (17.2)                       228 (17.8)
  Fatigue                                                             11 (16.2)              195 (16.1)                       206 (16.1)
  Fever                                                               23 (33.8)              362 (29.9)                       385 (30.1)
  Weight loss                                                         9 (13.2)               110 (9.1)                        119 (9.3)
  Vomiting                                                            9 (13.2)               208 (17.2)                       217 (17.0)
  Hemoptysis                                                          9 (13.2)               85 (7.0)                         94 (7.4)
  Known history of TB                                                 19 (28.0)              265 (21.9)                       284 (22.2)

^\*^Denominator reflects number of radiographs ordered. °Denominator reflects exclusion of missing disposition records
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